Stockscreener 앱 받기
50.73
1.74%
0.935
Vera Therapeutics Inc 주식(VERA)의 최신 뉴스
Vera Therapeutics (NASDAQ:VERA) Trading Up 5.3%Still a Buy? - MarketBeat
Vera Therapeutics Sees Optimism as Analysts Boost Price Targets - timothysykes.com
Vera Therapeutics (NASDAQ:VERA) Hits New 12-Month HighHere's Why - MarketBeat
Avoiding Lag: Real-Time Signals in (VERA) Movement - news.stocktradersdaily.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Wedbush Maintains Vera Therapeutics (VERA) Neutral Recommendation - Nasdaq
Vera Therapeutics stock hits 52-week high at 47.12 USD By Investing.com - Investing.com Canada
Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets - ts2.tech
Wedbush Raises Price Target on Vera Therapeutics to $33 From $23, Keeps Neutral Rating - marketscreener.com
Vera Therapeutics, Inc. $VERA Shares Bought by Jump Financial LLC - MarketBeat
Vera Therapeutics Completes Successful Stock Offering - TipRanks
Vera Therapeutics Announces Follow-On Public Offering - TradingView — Track All Markets
Soviero Asset Management LP Invests $707,000 in Vera Therapeutics, Inc. $VERA - MarketBeat
188,422 Shares in Vera Therapeutics, Inc. $VERA Acquired by Norges Bank - MarketBeat
Vera Therapeutics Prices $261 Million Public Offering - marketscreener.com
Vera Therapeutics prices public offering at $42.50 per share By Investing.com - Investing.com Nigeria
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - markets.businessinsider.com
Vera Therapeutics prices public offering at $42.50 per share - Investing.com
Vera Therapeutics prices public offering of Class A Common Stock at $42.50 per share - marketscreener.com
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock at $42.50 per Share - Quiver Quantitative
Polycythemia Vera Clinical Trial Pipeline Shows Potential with Active Contributions from 8+ Key Companies | DelveInsight - The Globe and Mail
Vera Therapeutics (NASDAQ:VERA) Shares Gap DownWhat's Next? - MarketBeat
Vera Therapeutics announces $200M public offering - MSN
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - markets.businessinsider.com
Evercore ISI Group Maintains Vera Therapeutics (VERA) Outperform Recommendation - Nasdaq
Vera Therapeutics Plans Offering of Common Shares - marketscreener.com
Vera Therapeutics (VERA) proposes $200M Class A share sale with 15% underwriter option - Stock Titan
Evercore ISI Group Raises Price Target for Vera Therapeutics (VE - GuruFocus
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bollard Group LLC Takes $1.51 Million Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Assessing Vera Therapeutics (VERA) Valuation After Adding Industry Veteran James R. Meyers to Its Board - Sahm
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $73.00 - MarketBeat
Vera Therapeutics, Inc. $VERA Shares Sold by Affinity Asset Advisors LLC - MarketBeat
Vera Therapeutics Inc. (VERA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Vera Therapeutics Stock is Climbing Higher - TipRanks
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $73 - 富途牛牛
Schroder Investment Management Group Reduces Stock Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics stock price target raised to $73 from $60 at TD Cowen - Investing.com UK
Vera Therapeutics exec Turner sells $400k in shares By Investing.com - Investing.com Canada
Vera Therapeutics exec Turner sells $400k in shares - Investing.com
Vera Therapeutics Executive Sells 10,000 Shares - TradingView
Will Vera Therapeutics Inc. stock reach Wall Street targets2025 Institutional Moves & Consistent Growth Stock Picks - Newser
Why Vera Therapeutics Inc. stock is trending among retail tradersMarket Volume Summary & Short-Term Trading Opportunity Alerts - Newser
Is Vera Therapeutics’ Recent 69% Surge Justified by Its Valuation in 2025? - Yahoo Finance
Vera Therapeutics rises 19.2% - MSN
Vera Therapeutics Stock Soars: Time to Buy? - StocksToTrade
Vera Therapeutics (VERA): Reassessing Valuation After Positive Phase 3 IgAN Data and Accelerated FDA Path - Yahoo Finance
Is Vera Therapeutics (VERA) Quietly Recasting Its Commercial Strategy With the Meyers Board Appointment? - Yahoo Finance
Vera Therapeutics (NASDAQ:VERA) Stock Price Up 6.7%Here's What Happened - MarketBeat
Vera Therapeutics, Inc. (VERA): A Top Gainer with Promising FDA Approvals - Meyka
Vera Therapeutics: Stock Rises As IgAN Approval Chances IncreaseI'm On Sidelines (VERA) - Seeking Alpha
0.56%
1.23%
자본화:
|
볼륨(24시간):